259 related articles for article (PubMed ID: 26827958)
1. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Doherty D; Dvorkin SA; Rodriguez EP; Thompson PD
Prostate; 2014 Feb; 74(3):273-85. PubMed ID: 24242708
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
4. 1,25(OH)
Erzurumlu Y; Aydogdu E; Dogan HK; Catakli D; Muhammed MT; Buyuksandic B
Cell Signal; 2023 Mar; 103():110577. PubMed ID: 36567009
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
7. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL
Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821
[TBL] [Abstract][Full Text] [Related]
8. SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.
Seo YK; Mirkheshti N; Song CS; Kim S; Dodds S; Ahn SC; Christy B; Mendez-Meza R; Ittmann MM; Abboud-Werner S; Chatterjee B
Mol Endocrinol; 2013 Jun; 27(6):925-39. PubMed ID: 23579488
[TBL] [Abstract][Full Text] [Related]
9. VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.
Solomon JD; Heitzer MD; Liu TT; Beumer JH; Parise RA; Normolle DP; Leach DA; Buchanan G; DeFranco DB
Mol Cancer Res; 2014 Aug; 12(8):1166-80. PubMed ID: 24825850
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
11. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer.
Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA
Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Yee SW; Campbell MJ; Simons C
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
Yang ES; Maiorino CA; Roos BA; Knight SR; Burnstein KL
Mol Cell Endocrinol; 2002 Jan; 186(1):69-79. PubMed ID: 11850123
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and prostate cancer.
Stewart LV; Weigel NL
Exp Biol Med (Maywood); 2004 Apr; 229(4):277-84. PubMed ID: 15044710
[TBL] [Abstract][Full Text] [Related]
15. Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer.
Peehl DM; Feldman D
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):307-15. PubMed ID: 15663994
[TBL] [Abstract][Full Text] [Related]
16. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer.
Ajibade AA; Kirk JS; Karasik E; Gillard B; Moser MT; Johnson CS; Trump DL; Foster BA
PLoS One; 2014; 9(2):e89555. PubMed ID: 24586868
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D-related therapies in prostate cancer.
Johnson CS; Hershberger PA; Trump DL
Cancer Metastasis Rev; 2002; 21(2):147-58. PubMed ID: 12465754
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.
Mooso B; Madhav A; Johnson S; Roy M; Moore ME; Moy C; Loredo GA; Mehta RG; Vaughan AT; Ghosh PM
Genes Cancer; 2010 Nov; 1(9):927-940. PubMed ID: 21552398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
